Table 5.
Multivariate Cox regression analyses for MACE
| MTES-IR | Incident MACE, n (%) |
HR (95% CI) | ||
|---|---|---|---|---|
| Model1 | Model2 | Model3 | ||
| Per 1 Unit increase | 243 (22.1%) | 1.05 (1.03–1.07) ** | 1.04 (1.03–1.06) ** | 1.05 (1.03–1.07) ** |
| Per 1 SD increase | 1.40 (1.24–1.60) ** | 1.35 (1.19–1.53) ** | 1.36 (1.20–1.55) ** | |
| Quartile 1 | 48 (17.4%) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Quartile 2 | 51 (18.4%) | 1.12 (0.75–1.66) | 1.09 (0.73–1.62) | 1.08 (0.72–1.60) |
| Quartile 3 | 62 (22.5%) | 1.47 (1.00–2.14) * | 1.34 (0.91–1.97) | 1.34 (0.91–1.98) |
| Quartile 4 | 82 (30.3%) | 2.19 (1.53–3.14) ** | 1.94 (1.34–2.79) ** | 1.97 (1.36–2.86) ** |
| p for trend | < 0.001 | < 0.001 | < 0.001 | |
Model 1: adjusted for age and gender
Model 2: adjusted for variables with p-value < 0.10, including age, hypertension, DM, previous stroke, LVEF, eGFR, TC, LDL-C, beta-blockers
Model 3: adjusted for age, gender, previous MI, previous stroke, previous PCI, admission for MI, hypertension, DM, hyperlipidemia, FH-CAD, TC, LDL-C, eGFR, LVEF, antiplatelet drugs, beta-blockers, statins, ACEI/ARB and hypoglycemic drugs
MACE the major adverse cardiovascular events, METS-IR the metabolic score for insulin resistance, HR hazard ratio, CI confidence interval, SD standard deviation
p values in bold are < 0.05
*p < 0.05
**p < 0.001